Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC By Ogkologos - July 7, 2025 372 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Higher Risk of Heart Failure Seen in Some Cancers March 26, 2018 Breaking down changes in NHS cancer waiting times in England August 17, 2023 40 K9 Officers Line Up Outside Terminally Ill Girl’s House For... March 26, 2019 24% of Breast Cancers Diagnosed Between Mammograms Could Have Been Detected... May 10, 2021 Load more HOT NEWS More Than One in 10 Patients With Lung Cancer Do Not... 5 questions the NHS Workforce Plan for England needs to answer Breast cancer surgery: ‘I’m proud of the tattoos inked across my... Holiday Lights Are My Favorite Thing
